The 36-month beta value for TYRA is at 1.10. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TYRA is 32.05M, and currently, shorts hold a 12.72% of that float. The average trading volume for TYRA on March 14, 2025 was 266.84K shares.
TYRA) stock’s latest price update
Tyra Biosciences Inc (NASDAQ: TYRA)’s stock price has increased by 7.12 compared to its previous closing price of 10.74. However, the company has seen a 5.16% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-11 that CARLSBAD, Calif., Feb. 11, 2025 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET Location: Virtual TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET Location: Boston Jefferies Biotech on the Beach Summit, March 11-12, 2025 Format: One-on-one investor meetings Location: Miami Barclays 27th Annual Global Healthcare Conference, March 11-13, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET Location: Miami A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
TYRA’s Market Performance
TYRA’s stock has risen by 5.16% in the past week, with a monthly drop of -4.44% and a quarterly drop of -29.11%. The volatility ratio for the week is 9.19% while the volatility levels for the last 30 days are 6.75% for Tyra Biosciences Inc The simple moving average for the last 20 days is -1.82% for TYRA stock, with a simple moving average of -35.60% for the last 200 days.
Analysts’ Opinion of TYRA
Many brokerage firms have already submitted their reports for TYRA stocks, with UBS repeating the rating for TYRA by listing it as a “Buy.” The predicted price for TYRA in the upcoming period, according to UBS is $28 based on the research report published on January 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see TYRA reach a price target of $31, previously predicting the price at $22. The rating they have provided for TYRA stocks is “Buy” according to the report published on October 18th, 2024.
Piper Sandler gave a rating of “Overweight” to TYRA, setting the target price at $33 in the report published on August 15th of the previous year.
TYRA Trading at -14.90% from the 50-Day Moving Average
After a stumble in the market that brought TYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.13% of loss for the given period.
Volatility was left at 6.75%, however, over the last 30 days, the volatility rate increased by 9.19%, as shares sank -7.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.20% lower at present.
During the last 5 trading sessions, TYRA rose by +3.93%, which changed the moving average for the period of 200-days by -34.35% in comparison to the 20-day moving average, which settled at $11.71. In addition, Tyra Biosciences Inc saw -17.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TYRA starting from Kjellson Nina S, who sale 5,401 shares at the price of $13.76 back on Feb 05 ’25. After this action, Kjellson Nina S now owns 443,885 shares of Tyra Biosciences Inc, valued at $74,324 using the latest closing price.
Canaan XI, LP, the Director of Tyra Biosciences Inc, proposed sale 120,000 shares at $13.75 during a trade that took place back on Feb 05 ’25, which means that Canaan XI, LP is holding shares at $1,650,000 based on the most recent closing price.
Stock Fundamentals for TYRA
Current profitability levels for the company are sitting at:
- -199.39 for the present operating margin
- 0.3 for the gross margin
The net margin for Tyra Biosciences Inc stands at -166.81. The total capital return value is set at -0.27. Equity return is now at value -28.66, with -27.06 for asset returns.
Based on Tyra Biosciences Inc (TYRA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.08. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -40.79.
Currently, EBITDA for the company is -79.59 million with net debt to EBITDA at 0.98. When we switch over and look at the enterprise to sales, we see a ratio of 1012.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.55.
Conclusion
In conclusion, Tyra Biosciences Inc (TYRA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
